Regulatory Framework Comparison

Understanding the differences between major regulatory frameworks helps navigate NAMs acceptance pathways. Each framework has distinct scope, validation requirements, and acceptance criteria.

      Strategic Tip: Framework selection depends on your product type (pharmaceutical vs. chemical), target markets, and endpoint requirements. Many NAMs satisfy multiple frameworks simultaneously.
    

Framework Overview

Framework	Scope	Members	NAMs Focus
ICH	Pharmaceuticals	FDA, EMA, PMDA + industry	Safety guidelines (S-series)
OECD	Chemicals & Pharma	38 member countries	Validated Test Guidelines
IATA	All sectors	OECD-developed approach	Weight-of-evidence integration
GHS	Chemical classification	70+ countries	Hazard classification endpoints

Validation Requirements

Framework	Validation Level	Timeline
ICH	Fit-for-purpose, flexible	Case-by-case
OECD	Formal ring trials required	2-4 years
IATA	Component validation	Flexible
GHS	OECD TG acceptance	Follows OECD

When to Use Each Framework

Drug Development → ICH guidelines + IATA approaches
Chemical Registration → OECD Test Guidelines + GHS
Cosmetics → OECD TGs (mandatory in EU)
Agrochemicals → OECD + regional requirements
Novel NAMs → IATA for early acceptance, OECD for formal validation

Key Differences

Flexibility: ICH/IATA most flexible; OECD most prescriptive
Speed: IATA fastest pathway; OECD formal validation slowest
Recognition: OECD has broadest mutual acceptance
Innovation: ICH and IATA encourage novel NAMs earlier

← Back to Regulatory Hub | Framework Overview

Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.

Free to share for educational purposes with attribution.